Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male.
On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current...
